Allergan plc Overview
Valuation check: AGN's ROE is -4.28%, below the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow-4.28%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Allergan plc (AGN) currently reports a ROE of -4.28%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Allergan plc's ROE history and peer comparisons.
Allergan plc's ROE of -4.28% is lower than the Healthcare sector average of 22.76%. That is roughly 118.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Allergan plc's current -4.28% should be judged against Healthcare norms (sector average: 22.76%) and against AGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -4.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Allergan plc, and consider following AGN for alerts when major investors trade the stock.
Allergan plc is classified in the Healthcare sector. On ROE, it currently shows -4.28% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGN with unrelated industries.
